Please assess the completion status of the following clinical trial:

Trial Title: SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who meet the following criteria at the start of treatment are eligible for the study:~* Receiving stable treatment with anti-hypertensive including ARB for at least 8 weeks at baseline (0W).~* Receiving stable anti-diabetic treatment with/without anti-diabetics for at least 8 weeks at baseline (0W).~* HbA1c\>=6.0%, \<10%~* Seated office SBP 130-159mmHg or DBP 80-99mmHg~* Nocturnal hypertension (SBP\>=115 mmHg) as measured by Home BP during 5days before baseline (0W).~* Age\>=20~Exclusion Criteria:~Patients who meet any of the following criteria are not eligible for the study:~* History of hypersensitivity to empagliflozin~* Breast-feeding, pregnant, possibly pregnant, or plan to become pregnant~* Treated with insulin or SU~* With renal dysfunction (eGFR\<45mL/min/1.73m2)~* With liver dysfunction (AST or ALT is 3 times higher than reference value)~* Hypotension (systolic blood pressure \< 90 mmHg)~* With pituitary gland dysfunction or adrenal gland dysfunction~* Heart failure patients whose NYHA class is IV~* Deemed ineligible for the study due to another reason by investigator~* History of diabetic ketoacidosis or diabetic come within 3 months before enrollment~* History of Acute myocardial infarction, unstable angina, cerebrovascular disease, or transient ischemic attack within 3 months before enrollment~* Patients who have undergone percutaneous transluminal coronary angioplasty (PCI) or coronary artery bypass graftin (CABG) within 3 months before enrollment~* Patients received SGLT2 inhibitor within 8 weeks before enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker \[ARB\]) and diabetes.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker \[ARB\]) and diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).